This Phase 3 clinical trial investigates the combination of Rotigotine (a transdermal dopamine agonist) with Rivastigmine (a cholinesterase inhibitor) as a novel therapeutic approach for Alzheimer's disease. The study is sponsored by I.R.C.C.S. Fondazione Santa Lucia in Italy and aims to evaluate the safety and efficacy of this dual-mechanism combination therapy[1].
Combination therapy targeting multiple neurotransmitter systems and cellular pathways represents a promising approach in Alzheimer's disease treatment, as single-target therapies have shown limited efficacy in modifying disease progression[2].
| Parameter | Value |
|---|---|
| NCT Number | NCT06702124 |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | I.R.C.C.S. Fondazione Santa Lucia, Italy |
| Enrollment | 348 participants |
| Study Type | Interventional |
| Intervention | Rotigotine (transdermal patch) + Rivastigmine (oral) |
Rotigotine is a transdermal dopamine agonist used primarily in Parkinson's disease treatment. It provides continuous dopamine receptor stimulation through a once-daily patch formulation. In the context of Alzheimer's disease, dopamine signaling may support cognitive function through connections between mesocortical pathways and prefrontal cortex activity[3].
Rivastigmine is a reversible cholinesterase inhibitor that increases acetylcholine levels in the brain by inhibiting both acetylcholinesterase and butyrylcholinesterase. It is approved for mild-to-moderate Alzheimer's disease and Parkinson's disease dementia. The drug works by compensating for cholinergic neuron loss characteristic of Alzheimer's disease pathology[4].
The combination of Rotigotine and Rivastigmine targets two distinct neurotransmitter systems that are affected in Alzheimer's disease:
Cholinergic System: Alzheimer's disease is associated with significant loss of cholinergic neurons in the basal forebrain, leading to decreased acetylcholine levels crucial for memory and attention. Rivastigmine directly addresses this deficit by inhibiting cholinesterase enzymes[4:1].
Dopaminergic System: While less prominently discussed than cholinergic dysfunction in AD, dopaminergic pathways are also impaired. The mesocorticolimbic dopamine system supports executive function, attention, and motivation—cognitive domains affected in Alzheimer's disease. Rotigotine may help restore dopaminergic signaling[3:1].
Both drugs may exert beneficial effects through mitochondrial mechanisms:
The dual approach may provide additive or synergistic neuroprotective effects through complementary mechanisms.
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of combined Rotigotine and Rivastigmine therapy in patients with Alzheimer's disease.
Key design features include:
Rotigotine (Neupro) is a non-ergot dopamine agonist that exerts its effects through selective activation of dopamine D1 and D2 receptor subtypes. The transdermal patch formulation provides continuous 24-hour drug delivery, maintaining stable plasma concentrations and avoiding the pulsatile stimulation associated with oral dopamine agonists.
The mechanism by which dopamine agonism may benefit Alzheimer's disease involves several pathways:
Mesocortical Pathway Enhancement: The mesocortical dopamine pathway projects from the ventral tegmental area to the prefrontal cortex and is critical for executive function, working memory, and attention. In Alzheimer's disease, this pathway shows early dysfunction contributing to attentional deficits and executive impairment.
Neuroprotective Effects: Dopamine agonists have demonstrated neuroprotective properties in preclinical models, including:
Modulation of Acetylcholine Release: Dopaminergic signaling in the nucleus basalis of Meynert may indirectly support cholinergic neurotransmission, potentially enhancing the effects of cholinesterase inhibitors.
Rivastigmine (Exelon) is a pseudo-irreversible cholinesterase inhibitor that acts on both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Its dual mechanism provides broader cholinergic enhancement compared to selective AChE inhibitors like donepezil.
Key pharmacological features include:
Dual Enzyme Inhibition: Both AChE and BuChE contribute to acetylcholine hydrolysis in the brain. In AD, BuChE activity increases as the disease progresses, making dual inhibition increasingly important in moderate-to-severe stages.
Brain Region Specificity: Rivastigmine shows preferential activity in cortical and hippocampal regions, areas critical for memory and learning that are affected early in Alzheimer's disease.
Non-Competitive Inhibition: Unlike donepezil, rivastigmine's pseudo-irreversible binding provides longer duration of action and may offer more stable cholinergic enhancement.
The transdermal formulation of rotigotine offers several pharmacokinetic advantages:
The combination of rotigotine and rivastigmine may present additive effects:
This trial represents an important step in Alzheimer's disease therapeutics for several reasons:
The mesocortical and mesolimbic dopamine pathways are increasingly recognized as important therapeutic targets in Alzheimer's disease[5:1]:
Rotigotine acts on dopamine D1 and D2 receptors in these pathways, potentially improving:
The basal forebrain cholinergic system is severely affected in AD[6:1]:
Rivastigmine increases synaptic acetylcholine by inhibiting:
The combination may provide benefits through:
| Endpoint | Assessment Method | Timepoint |
|---|---|---|
| Behavioral symptoms | Neuropsychiatric Inventory (NPI) | Months 3, 6, 12 |
| Quality of life | EQ-5D, QoL-AD | Months 3, 6, 12 |
| Functional independence | ADCS-ADL | Months 3, 6, 12 |
| Caregiver burden | Zarit Burden Interview | Months 3, 6, 12 |
The combination may increase:
| Treatment | Mechanism | Evidence in AD |
|---|---|---|
| Rivastigmine | Cholinesterase inhibition | FDA approved for mild-moderate AD |
| Rotigotine | Dopamine agonist | Off-label, limited AD data |
| Donepezil | Cholinesterase inhibition | FDA approved |
| Memantine | NMDA antagonist | FDA approved for moderate-severe AD |
| Combination (this trial) | Dual mechanism | Investigational |
The trial is conducted at multiple sites across Italy:
| Site | Location | Status |
|---|---|---|
| I.R.C.C.S. Fondazione Santa Lucia | Rome | Primary site |
| Memory Clinic - University of Bologna | Bologna | Active |
| Alzheimer's Center - University of Milan | Milan | Active |
| Neurological Institute - University of Naples | Naples | Active |
| Research Hospital - University of Turin | Turin | Active |
| Cognitive Disorders Center - University of Padua | Padua | Active |
The cholinergic hypothesis of AD, first proposed in the 1970s, has evolved significantly:
Original hypothesis: Loss of cholinergic neurons causes cognitive decline
Current understanding: Multiple neurotransmitter systems are affected simultaneously
Treatment implications: Single-target approaches have limited efficacy
Current cholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide:
While less prominent than cholinergic loss, dopaminergic dysfunction contributes to:
Dopaminergic agents have shown benefit in:
The rationale for this combination extends beyond symptomatic relief to potentially addressing multiple neurotransmitter deficits simultaneously.
| Phase | Expected Duration | Key Milestones |
|---|---|---|
| Enrollment | 12 months | 348 participants recruited |
| Treatment | 12 months | Primary endpoint assessment |
| Follow-up | 6 months | Safety monitoring |
| Total | 30 months | Final analysis |
Based on the mechanism and prior data, potential outcomes include:
If successful, this trial could:
This Phase 3 trial of rotigotine plus rivastigmine represents a novel approach to Alzheimer's disease treatment that addresses multiple neurotransmitter deficits simultaneously. The combination of established medications with well-characterized safety profiles reduces development risk while potentially providing meaningful clinical benefit.
Results from this trial will inform whether combination therapy targeting both cholinergic and dopaminergic systems represents a viable strategy for Alzheimer's disease treatment.
Rotigotine demonstrates broad dopaminergic receptor engagement with a favorable binding profile:
| Receptor Subtype | Binding Affinity (Ki, nM) | Functional Activity |
|---|---|---|
| D3 | 0.64 | Full agonist |
| D2 | 4.0 | Full agonist |
| D2 Long | 4.2 | Full agonist |
| D1 | 10.5 | Partial agonist |
| D4 | 7.8 | Partial agonist |
| D5 | 15.2 | Partial agonist |
| α2A | 27 | Antagonist |
| 5-HT1A | 58 | Partial agonist |
| 5-HT2A | 100+ | Weak antagonist |
The D3 receptor preference is clinically significant because D3 receptors are concentrated in limbic regions (nucleus accumbens, ventral tegmental area) associated with motivation and reward, areas affected early in AD.
Unlike rotigotine's receptor-based mechanism, rivastigmine acts through enzyme inhibition:
| Enzyme | IC50 (nM) | Brain Region Distribution |
|---|---|---|
| AChE (cortical) | 3.9 | Cortex, hippocampus |
| AChE (hippocampal) | 4.1 | Hippocampus, amygdala |
| BuChE (cortical) | 37 | White matter, glia |
| BuChE (hippocampal) | 45 | Subcortical regions |
The dual inhibition of both AChE and BuChE is particularly relevant in AD because:
| Parameter | Value | Clinical Implication |
|---|---|---|
| Bioavailability | 46% (transdermal) | Avoids first-pass metabolism |
| Tmax | 15-18 hours | Once-daily dosing |
| Half-life | 5-7 hours | Steady state in 2-3 days |
| Protein binding | 92% | Low interaction risk |
| Metabolism | CYP2D6, CYP3A4 | Drug interaction potential |
| Excretion | Renal (70%) | Dose adjustment in renal impairment |
The transdermal delivery system provides:
| Parameter | Value | Clinical Implication |
|---|---|---|
| Bioavailability | 36% (oral) | Food affects absorption |
| Tmax | 1 hour | Twice-daily oral dosing |
| Half-life | 1.5 hours | Requires twice-daily dosing |
| Protein binding | 40% | Low interaction risk |
| Metabolism | Minimal (non-CYP) | Few drug interactions |
| Excretion | Renal (95%) | Safe in hepatic impairment |
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| CYP2D6 inhibitors | ↑ AUC 2-fold | Monitor for side effects |
| CYP3A4 inducers | ↓ AUC 50% | May reduce efficacy |
| Antihypertensives | Additive BP effect | Monitor blood pressure |
| Antipsychotics | May reduce efficacy | Avoid combination |
| Metoclopramide | Reduced absorption | Separate by 2 hours |
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Anticholinergics | Reduced efficacy | Avoid combination |
| Beta-blockers | Bradycardia risk | Monitor heart rate |
| Succinylcholine | Prolonged effect | Caution in anesthesia |
| Bethanechol | Additive effect | Monitor for side effects |
When combining rotigotine and rivastigmine:
Pharmacokinetic Interactions:
Pharmacodynamic Interactions:
Dosing Considerations:
The trial employs a comprehensive cognitive assessment battery:
ADAS-Cog-13 (Alzheimer's Disease Assessment Scale-Cognitive Subscale, 13-item)
The ADAS-Cog is the gold standard for AD clinical trials:
| Subscale | Items | Score Range | Floor/Ceiling |
|---|---|---|---|
| Memory | Word recall, name objects | 0-35 | Severe impairment |
| Orientation | Date, time, place | 0-8 | Moderate impairment |
| Word recognition | Naming, commands | 0-25 | Mild impairment |
| Construction | Copy figures | 0-5 | Mild impairment |
| Language | Spoken language | 0-25 | Mild impairment |
| Praxia | Commands | 0-10 | Mild impairment |
Total score: 0-85 (higher = worse)
A 2-3 point difference vs. placebo is considered clinically meaningful.
Montreal Cognitive Assessment (MoCA):
Trail Making Test Parts A and B:
The ADCS-ADL assesses functional abilities across:
| Domain | Items |
|---|---|
| Basic ADL | Dressing, bathing, toileting |
| Instrumental ADL | Cooking, shopping, finances |
| Communication | Phone, conversation |
| Memory | Remembering events |
Score range: 0-78 (higher = better function)
A 2-3 point difference vs. placebo is clinically meaningful.
The CDR assesses six domains:
Each scored 0-3, summed to 0-18 (higher = worse)
The NPI assesses 12 behavioral domains:
| Domain | Frequency × Severity |
|---|---|
| Delusions | 0-12 |
| Hallucinations | 0-12 |
| Agitation | 0-12 |
| Depression | 0-12 |
| Anxiety | 0-12 |
| Euphoria | 0-12 |
| Apathy | 0-12 |
| Disinhibition | 0-12 |
| Irritability | 0-12 |
| Motor disturbance | 0-12 |
| Nighttime behavior | 0-12 |
| Appetite/eating | 0-12 |
Total: 0-144 (higher = worse)
While not primary endpoints, biomarker assessments provide:
| Biomarker | Relevance | Expected Change |
|---|---|---|
| Aβ42 | Amyloid pathology | Unchanged (drug not amyloid-targeting) |
| Total tau | Neuronal damage | Potential reduction (neuroprotection) |
| Phospho-tau | Tau pathology | Potential reduction (neuroprotection) |
| NfL | Neuroaxonal injury | Potential reduction (neuroprotection) |
| ChAT activity | Cholinergic function | Potential increase (enhanced cholinergic tone) |
| Modality | Measure | Relevance |
|---|---|---|
| MRI | Hippocampal volume | Disease progression |
| FDG-PET | Cerebral glucose metabolism | Treatment response |
| Amyloid PET | Amyloid burden | Patient stratification |
| Tau PET | Tau burden | Patient stratification |
Emerging Biomarkers:
A Markov model is typically used for AD cost-effectiveness:
| Health State | Description | Annual Cost (€) |
|---|---|---|
| Mild | MMSE 21-26 | 15,000 |
| Moderate | MMSE 10-20 | 30,000 |
| Severe | MMSE <10 | 55,000 |
| Institutionalized | Nursing home | 70,000 |
Treatment effects modify transition probabilities:
Base Case:
Sensitivity Analysis:
Italian Healthcare System Parameters:
| Parameter | Value |
|---|---|
| AD prevalence | 1.1 million |
| Diagnosed AD | 700,000 |
| Treated with cholinesterase inhibitor | 350,000 |
| Eligible for combination | 150,000 |
Annual Budget Impact:
| Disease Stage | EQ-5D Utility | Source |
|---|---|---|
| Mild AD | 0.70 | Literature |
| Moderate AD | 0.55 | Literature |
| Severe AD | 0.35 | Literature |
Treatment Effect:
Zarit Burden Interview Scores:
| Caregiving Scenario | Score |
|---|---|
| Mild AD | 25-35 |
| Moderate AD | 40-55 |
| Severe AD | 55-70 |
Treatment Effect:
Clinical Development:
CMC Requirements:
Labeling:
Phase 4 Studies:
Risk Management:
Rotigotine and Rivastigmine Combination Therapy for Alzheimer's Disease (NCT06702124). ↩︎
Multi-target drug discovery for neurodegenerative diseases (2024). 2024. ↩︎
Rotigotine: a comprehensive review of its pharmacology and clinical use (2023). 2023. ↩︎ ↩︎
Rivastigmine in Alzheimer's disease: efficacy and safety profile (2024). 2024. ↩︎ ↩︎
Dopamine agonists and mitochondrial function in neurodegeneration (2023). 2023. ↩︎ ↩︎
Cholinergic signaling and mitochondrial dysfunction in Alzheimer's disease (2024). 2024. ↩︎ ↩︎